

# Natera Reports Second Quarter

## Recent Accomplishments & Highlights:

“Strong momentum driven by record volume levels and higher ASPs enabled us to again raise our 2022 revenue guidance.”


“We are proud to have helped close to 500,000 patients in Q2. As we scale the business, we now see a clear path to reach a cash flow breakeven quarter by mid-2024. A key highlight in the quarter was receiving Medicare coverage for Signatera in muscle-invasive bladder cancer, representing the fourth coverage decision by Medicare for Signatera,” said Steve Chapman, Natera’s Chief Executive Officer.




Generated total revenues of **\$198.2 million**.



**\$194.6 million** in product revenues, **an increase of 39.3%** from the second quarter of 2021.



Processed close to **500,000 tests**, a 33% increase over the second quarter of 2021.



Increased 2022 revenue guidance from \$790-810 million to **\$805-825 million**.

## Growth highlights:

- **Secured Medicare coverage** for muscle invasive bladder cancer; **fourth** coverage decision for Signatera™.
- Selected to participate in UnitedHealthcare’s Preferred Laboratory Network after a **rigorous review process**.
- Completed enrollment in **RenaCARE study** for Renasight™ test, with more than **1,700 patients** across **30+ sites**.
- Presented substantial new **Signatera™ data** sets across multiple cancer types at the 2022 ASCO Annual Meeting.
- Published **Trifecta study** for Prospera™ Kidney in Transplantation; **largest prospective**, multi-site, fully biopsy matched **study to date**.
- Executive Chairman Matt Rabinowitz announced **additional equity investment** in Natera.



**Dr. Minetta Liu** joined Natera as Chief Medical Officer for Oncology.